Researchers recently presented data on ArQule's
( ARQL ) ARQ 092 at
the American Association for Cancer Research (AACR) Annual Meeting
held in Washington, D.C. The data revealed that the candidate
inhibits the AKT pathway and proved to be quite safe in an ongoing
phase I clinical trial.
ARQ 092 is a selective AKT inhibitor, which was invented from
the proprietary ArQule Kinase Inhibitor Platform (AKIP). ARQ 092
was tested in patients with a broad range of advanced or metastatic
solid tumors, including colorectal, endometrial and neuroendocrine
cancers for safety and activity. The researchers will test ARQ 092
for efficacy once they identify the maximum tolerated dose.
We note that ArQule regained its rights from Daiichi Sankyo to
the AKT program and to candidate ARQ 092 after the latter decided
to terminate the license and co-commercialization agreement. We
note that Daiichi Sankyo and ArQule entered into a license
agreement for the development of ARQ 092 in Nov 2011.
As per the license agreement, Daiichi Sankyo had exclusive
rights for the development, manufacturing and marketing of ARQ 092
on a global basis. In exchange, ArQule received a $10 million
upfront payment from Daiichi Sankyo in Nov 2011 along with support
for the ongoing phase I trial on ARQ 092.
Apart from ARQ 092, ArQule's pipeline also includes oncology
candidate ARQ 197 (tivantinib).
In Jan 2013, ArQule and partner Daiichi Sankyo initiated a phase
III METIV-HCC -- MET-high patients with tivantinib in
hepatocellular carcinoma (HCC) -- trial on ARQ 197.
ArQule currently carries a Zacks Rank #3 (Hold). Right now,
other companies in the biopharma space such as Gliead
Sciences ( GILD ), Agenus
Inc ( AGEN
) and Biodel Inc ( BIOD ) look better
placed with a Zacks Rank #2 (Buy).AGENUS INC (AGEN): Free Stock Analysis ReportARQULE INC (ARQL): Free Stock Analysis ReportBIODEL INC (BIOD): Free Stock Analysis ReportGILEAD SCIENCES (GILD): Free Stock Analysis
ReportTo read this article on Zacks.com click here.Zacks Investment